Amorphous metal-organic frameworks

Patent metadata

Field	Value
Publication number	US-11083795-B2
Application number	US-201615735145-A
Country	US
Kind code	B2
Filing date	Jun 24, 2016
Priority date	Jun 24, 2015
Publication date	Aug 10, 2021
Grant date	Aug 10, 2021

Abstract

The invention provides an amorphous metal-organic framework for use in methods of treatment. The amorphous metal-organic framework may hold a component for delivery. The amorphous metal-organic framework is obtained or is obtainable by amorphization of a crystalline amorphous metal-organic framework holding the component. The amorphous metal-organic framework may be a zirconium-containing or a bismuth-containing metal-organic framework, such as a framework having arylcarboxylate ligands, such as benzenedicarboxylate ligands.

First claim

The invention claimed is:

1. A method of delivering a component to a target location, the method comprising the steps of:
(i) providing an amorphous metal-organic framework at a target location, wherein the amorphous metal-organic framework holds a component, wherein the component is an agrochemical, the component is not molecular iodine (I 2 ) and the component has a molecular weight that is at least 100; and
(ii) permitting the release of the component from the amorphous metal-organic framework, thereby to provide the component at the target location.

2. An amorphous metal-organic framework holding a component, wherein the component is an agrochemical, the component is not molecular iodine (I 2 ) and the component has a molecular weight that is at least 100.

3. The amorphous metal-organic framework according to claim 2 , wherein the metal-organic framework is a zirconium-containing metal-organic framework.

4. The amorphous metal-organic framework according to claim 3 , wherein the zirconium-containing metal-organic framework has benzenedicarboxylate ligands.

5. The amorphous metal-organic framework according to claim 4 , wherein the benzenedicarboxylate ligands are 1,4 benzenedicarboxylate ligands.

6. The amorphous metal-organic framework according to claim 2 , wherein the metal-organic framework is UiO 66, NU-1000 or NU-901, such as UiO 66.

7. The amorphous metal-organic framework according to claim 2 , wherein the metal-organic framework is a bismuth-containing metal-organic framework, such as wherein the metal-organic framework is CAU-7.

8. The amorphous metal-organic framework according to claim 2 , wherein the component has:
(i) three or more atoms; and/or
(ii) one or more carbon atoms; and/or
(iii) a molecular weight of at least 255.

9. The amorphous metal-organic framework according to claim 2 , wherein the amorphous metal-organic framework is obtainable by amorphization of a crystalline metal-organic framework holding the component, such as wherein the amorphization is a ball milling of the crystalline metal-organic framework holding the component.

10. The method of claim 1 , wherein the target location is within a cell, such as cell that is ex vivo.

11. The method of claim 1 , wherein the step of providing the amorphous metal-organic framework at a target location includes passing the amorphous metal-organic framework through a cell wall, such as a eukaryotic cell wall.

12. The method of claim 1 , wherein the amorphous metal-organic framework releases the component upon treatment with base, such as an aqueous basic solution, such as an aqueous basic solution at physiological pH.

13. The method of claim 1 , wherein the component is released into an aqueous phase.

14. The method of claim 1 , wherein:
(i) no more than 50% of the component is releasable or released from the amorphous metal-organic framework after 48 hours from initial release; and/or
(ii) at least 80% of the component is released or releasable from the amorphous metal-organic framework, such as at least 80% of the component is released or releasable from the amorphous metal-organic framework after 30 days from initial release.

15. The method of claim 1 , wherein the metal-organic framework is a zirconium-containing metal-organic framework.

16. The method of claim 15 , wherein the zirconium-containing metalorganic framework has benzenedicarboxylate ligands, such as wherein the benzenedicarboxylate ligands are 1,4-benzenedicarboxylate ligands.

17. The method of claim 1 , wherein the metal-organic framework is UiO-66, NU-1000, or NU-901, such as UiO-66.

18. The method of claim 1 , wherein the method is a method of treating a plant or a plant material.

19. The method of claim 1 , wherein the agrochemical is a herbicide, insecticide, or fungicide.

20. The amorphous metal-organic framework of claim 2 , wherein the agrochemical is a herbicide, insecticide, or fungicide.

Assignees

• Cambridge Entpr Ltd

Inventors

• Orellana-Tavra Claudia
• Slater Nigel
• Fairen-Jimenez David
• Teplensky Michelle
• Baxter Emma
• Bennett Thomas
• Cheetham Anthony

Classifications

• A61K47/12 Primary

  Carboxylic acids; Salts or anhydrides thereof · CPC title

• A61K31/513

  having oxo groups directly attached to the heterocyclic ring, e.g. cytosine · CPC title

• A61K31/277

  having a ring, e.g. verapamil · CPC title

• A61K31/713

  Double-stranded nucleic acids or oligonucleotides · CPC title

• A61K31/19

  Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title